

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AUSTAR**

**Austar Lifesciences Limited**

**奧星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

## **UPDATE ON FINANCIAL INFORMATION**

This announcement is made by Austar Lifesciences Limited (“**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules).

The board (“**Board**”) of directors (“**Directors**”, each a “**Director**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the Board’s preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2018 (the “**Current Period**”) and other information currently available, the Group is expected to record a decrease in the loss attributable to shareholders of the Company for the Current Period as compared to that for the six months ended 30 June 2017, which was mainly attributable to the following factors: (i) an increase in revenue mainly resulting from the increased in closing value of backlog as at 31 December 2017 as compared with that of 31 December 2016, which part of amount were recognised as revenue in the Current Period; (ii) an increase in gross profit mainly attributable to the improved project execution management and cost control measures for the business segment of Liquid and Bioprocess System which is the major revenue contributor of the Group for the Current Period as compared with the corresponding period in 2017; and (iii) an increase in revenue and gross profit from the business segment of Life Science Consumables. Nonetheless, the effect of such increase is partially offset by the increase in administrative expenses, selling and marketing expenses and research and development expenses.

The information contained in this announcement is only based on the preliminary assessment by the management of the Company by information currently available to the Group including the unaudited consolidated management accounts of the Group for the six months ended 30 June 2018 and is not based on any figure or information which has been audited or reviewed by the Company’s auditors and may be subject to adjustments and changes. Details of the Group’s financial information and performance will be disclosed when the Group’s interim results for the six months ended 30 June 2018 are announced.

**Shareholders of the Company and potential investors should exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 24 July 2018

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yewwu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*